Quick Summary
Embopag 50mg Tablet
Last updated on 31 Mar 2026 | 09:29 AM (IST)
₹6038
MRP: ₹13125
(You Save ₹7087)
28 TABLET(s) IN A BOTTLE
54% OFF
₹6038
MRP: ₹13,125.00
Inclusive of all taxes
54% Off
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Substitutes
Elpag 50mg Tablet
SHILPA MEDICARE...
₹ 123.80/tablet
42% cheaper
Eltromag 50mg Tablet
CIPLA LTD
₹ 124.00/tablet
42% cheaper
Eltrombo 50mg Tablet
APRAZER HEALTHC...
₹ 125.57/tablet
41% cheaper
Elromo 50mg Tablet
ZYDUS CADILA
₹ 125.71/tablet
41% cheaper
Introduction
Embopag 50mg Tablet is an anticoagulant drug belonging to the thrombopoietin (TPO) receptor agonist category, containing the active ingredient Eltrombopag. It treats low platelet counts caused by primary immune thrombocytopenia (ITP) or hepatitis C (HCV) infection, which aligns with Embopag 50mg Tablet uses in clinical practice. ITP is an autoimmune disorder where the immune system destroys platelets, which are essential for clotting and protecting blood vessel walls. Low platelet levels can lead to severe bleeding and bruising. This tablet is also used in adults to treat low blood counts caused by severe aplastic anemia, a condition where the bone marrow fails to produce enough new blood cells.
What is Embopag 50mg Tablet for? This medication is primarily used to increase platelet production in patients with ITP, hepatitis C, and severe aplastic anemia. By stimulating the thrombopoietin receptor, Embopag 50mg Tablet helps prevent bleeding complications related to low platelet counts.
This medicine should not be used in individuals who have known hypersensitivity or allergic reactions to the drug or its components. Allergic reactions can range from mild to severe and may include symptoms like rash, itching, swelling, dizziness, or difficulty breathing. Embopag 50mg Tablet is contraindicated in patients with severe liver impairment or active liver disease, as it can cause hepatotoxicity, indicated by increased liver enzymes and bilirubin levels. Your doctor may recommend regular eye tests for cataracts or bleeding in the retina, especially during prolonged use of the medication.
If you stop taking this tablet, your platelet count is likely to drop again within several days. Your doctor will monitor your platelet count and adjust the dosage to avoid too high a platelet count, which can increase the risk of blood clots.
Embopag 50mg price can vary depending on location and pharmacy. It's important to consult with your local pharmacy for the most accurate price information. Many patients inquire about buying Embopag 50mg online to find convenient purchasing options.
Uses
Embopag 50mg Tablet is used to treat,
Low platelet counts are caused by primary immune thrombocytopenia (ITP) or hepatitis C virus (HCV) infection.
Severe aplastic anaemia.
How Admapag 50mg Tablet Works
Embopag 50mg Tablet stimulates megakaryocytes (the large bone marrow cells) responsible for producing platelets. By raising the number of platelets in the blood, this drug prevents bleeding and bruising.
Interaction of Embopag 50mg Tablet with other drugs
Inform your healthcare provider about your medicines, including prescription, over-the-counter, nutritional or vitamin supplements, and herbal products. Certain medications include antacid medicines, statins, ciclosporin, methotrexate, topotecan, lopinavir, or ritonavir, and vitamin and mineral supplements may interact with Embopag 50mg Tablet and reduce effectiveness by causing undesirable side effects.
Storage conditions
Store Embopag 50mg Tablet at room temperature (25°C).
Keep the medicine out of reach of children and pets.
How to Take Embopag 50mg Tablet
It is an orally available prescription drug. Your doctor will decide the dose and duration of the drug based on the disease condition and other factors. Always take an Embopag 50mg Tablet as prescribed by your doctor. Take the tablet with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water.
Safety Advices
Pregnancy
Embopag 50mg Tablet is not recommended for pregnant patients because it may cause fetal harm. You must inform your doctor if you are pregnant, suspecting, or planning to get pregnant during the treatment.
Breast Feeding
It is not known whether Embopag 50mg Tablet passes into breast milk. If you are breastfeeding or planning to breastfeed, tell your doctor.
Lungs
It is unknown whether Embopag 50mg Tablet can be prescribed for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Embopag 50mg Tablet should be cautiously administered in patients with severe liver diseases. Dose adjustments are necessary for severe liver failure. Inform your doctor if you have liver issues before initiating the therapy.
Alcohol
It is unknown whether alcohol may interact with the Embopag 50mg Tablet. Inform your physician if you drink alcoholic beverages.
Driving
Driving vehicles or operating heavy machinery is unsafe after taking the Embopag 50mg Tablet. It may cause dizziness and impair concentration.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Embopag 50mg Tablet side effects are
Common:
Nausea
Diarrhea, abdominal pain
Common cold
Cough
Respiratory tract infection
Back pain
High temperature, cough
Loss of appetite
Hair loss
Swelling in feet or hands
Headache, dizziness
Mouth and throat pain
Joint pain.
Expert tips
Avoid consuming the following 2 hours before or 4 hours after taking Embopag 50mg Tablet: Diary Products, Antacids, Supplements containing iron and aluminium
If you miss a dose, take the next dose at the usual scheduled time.
Do not take more than one dose per day.
Do not stop taking Embopag 50mg Tablet without consulting your doctor.
If your doctor discontinues the treatment, your platelet count will be monitored weekly for four weeks.
If you have any doubts or questions about how to take this medicine, consult your doctor for guidance.
FAQs
Q1.
What is ITP?
Immune thrombocytopenia, also known as ITP, is a rare blood disorder. People with ITP have insufficient platelets in their blood. A low platelet count can cause bruising and bleeding.
Q2.
Who should not use Embopag 50mg Tablet?
People with immune (primary thrombocytopenia (ITP) and children under one should not use Embopag 50mg Tablet. It is also not suggested for people with severe aplastic anemia and hepatitis C.
Q3.
Will you be monitored during treatment with Embopag 50mg Tablet?
Yes, you will be monitored during tablet. Your healthcare provider will regularly access your white blood cell, platelets, blood clotting factors, heart rate, eye test, and complete blood count.
Q4.
Is it safe to take Embopag 50mg Tablet on an empty stomach?
Yes, Embopag 50mg Tablet should be taken on an empty stomach. Because antacids, mineral and vitamin supplements (iron, calcium, magnesium, aluminum, selenium, and zinc), dairy products, calcium-enriched foods, and fortified juices interfere with this drug absorption. So, please take them at least two hours before or four hours after taking the medication.
Q5.
What happens if you discontinue using Embopag 50mg Tablet?
If you discontinue using Ltromb Tablet suddenly, it decreases platelet count as it can lead to severe bleeding. However, telling your healthcare practitioner before discontinuing this medication is advisable.
Q6.
What are the storage conditions for Embopag 50mg Tablet?
This tablet at 25°C and out of the reach of children. After the expiration date, do not use this medication.
Fact Box
Molecule name | Eltrombopag |
Therapeutic class | Anticoagulant |
Pharmacological class | Thrombopoietin (TPO) receptor agonist |
Indications | 1. Low platelet counts caused by immune primary thrombocytopenia (ITP) or hepatitis C virus (HCV) infection. 2. Severe aplastic anaemia. |
References
Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on Jan 2022] [Accessed on 22 May 2023], https://www.medicines.org.uk/emc/files/pil.508.pdf
GlaxoSmithKline, US Food and Drug Administration, [ Revised on October 2008] [Accessed on 22 May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022291lbl.pdf
Revolade, Annex I summary of Product Characteristics - European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/revolade-epar-product-information_en.pdf [Accessed on 22 May 2023].
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Vikas B S
Pharm D
Reviewed By
Dr. Abhishaanth Prabu
MBBS
Last updated : 31 Mar 2026 | 09:29 AM (IST)
Want to know more?
Read Our Editorial Policy
